KEYNOTE-522 Archives - Medical Conferences

KEYNOTE-522 finds prognostic value of TMB and gene profiles in TNBC

Presented By

Dr Joyce O’Shaughnessy, Baylor University Medical Center, USA

Trial

Phase 3, KEYNOTE-522

Conference

SABCS 2024

Type

Peer-reviewed article

23 January 2025 11:36

More highlights in Breast Cancer

Trial

HERA, NATALEE, KEYNOTE-522, HypoG-01

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 12:20

Analysis by residual cancer burden further clarifies effect of pembrolizumab

Presented By

Prof. Lajos Pusztai, Yale School of Medicine, CT, USA

Trial

Phase 3, KEYNOTE-522

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 11:26

Neoadjuvant pembrolizumab plus chemotherapy benefits event-free survival in TNBC

Presented By

Prof. Peter Schmid, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-522

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:45

SABCS 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

SABCS 2021

10 January 2022 20:59

Neoadjuvant + adjuvant pembrolizumab improves pCR in triple-negative breast cancer with lymph node involvement

Trial

KEYNOTE-173, Phase 1b ; I-SPY 2, Phase 2 ; KEYNOTE-522, Phase 3

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 22:56

Triple negative breast cancer gets positive news: KEYNOTE-522 interim results

Presented By

Prof. Peter Schmid, Queen Mary University of London, UK

Trial

Phase 3, KEYNOTE-522

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 23:12